Freshfields Advised Leerink Partners, Evercore ISI, Cantor and RBC on 4DMT’s $100m Underwritten Offering of Common Stock and Pre-Funded Warrants

Freshfields Advised Leerink Partners, Evercore ISI, Cantor and RBC on 4DMT’s $100m Underwritten Offering of Common Stock and Pre-Funded Warrants

Global Leading Law firm Freshfields has advised Leerink Partners, Evercore ISI and Cantor as joint book-running managers and RBC Capital Markets as co-manager in connection with 4D Molecular Therapeutics’ $100 million underwritten offering of common stock and pre-funded warrants.

The offering includes 8,385,809 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,128,949 shares of common stock. The shares of common stock are being sold at a price of $10.51 per share and the pre-funded warrants are being sold at a price of $10.5099 per pre-funded warrant, which represents the per share price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The offering closed on November 7, 2025.

The Freshfields team was led by capital markets Phillip Stoup (Partner), Jacqueline Marino (Partner), Vinita Kailasanath (Partner), and Katherine Kim (Senior Associate), and Yunah Ko (Associate), Breandan Mchale (Associate), Juliana Zhang (Associate), and Jay Cosel (Counsel).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.